|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-4-28
|
|
pubmed:abstractText |
We conducted a randomised phase II study to assess the safety and efficacy of standard versus high-dose pemetrexed in platinum-resistant epithelial ovarian cancer (PR-EOC). The expression of ten genes was also examined as potential biomarkers of pemetrexed/platinum activity.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ERCC1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases,
http://linkedlifedata.com/resource/pubmed/chemical/Folic Acid Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamates,
http://linkedlifedata.com/resource/pubmed/chemical/Guanine,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Transport Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Platinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/SLC19A2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/pemetrexed
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1415-23
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19168349-Adult,
pubmed-meshheading:19168349-Aged,
pubmed-meshheading:19168349-Antimetabolites, Antineoplastic,
pubmed-meshheading:19168349-Chi-Square Distribution,
pubmed-meshheading:19168349-DNA-Binding Proteins,
pubmed-meshheading:19168349-Disease-Free Survival,
pubmed-meshheading:19168349-Double-Blind Method,
pubmed-meshheading:19168349-Drug Administration Schedule,
pubmed-meshheading:19168349-Drug Resistance, Neoplasm,
pubmed-meshheading:19168349-Endonucleases,
pubmed-meshheading:19168349-Female,
pubmed-meshheading:19168349-Folic Acid Antagonists,
pubmed-meshheading:19168349-Gene Expression,
pubmed-meshheading:19168349-Glutamates,
pubmed-meshheading:19168349-Guanine,
pubmed-meshheading:19168349-Humans,
pubmed-meshheading:19168349-Kaplan-Meier Estimate,
pubmed-meshheading:19168349-Membrane Transport Proteins,
pubmed-meshheading:19168349-Middle Aged,
pubmed-meshheading:19168349-Ovarian Neoplasms,
pubmed-meshheading:19168349-Peritoneal Neoplasms,
pubmed-meshheading:19168349-Platinum Compounds,
pubmed-meshheading:19168349-Prognosis,
pubmed-meshheading:19168349-Survival Rate,
pubmed-meshheading:19168349-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
|
|
pubmed:affiliation |
University Hospital Leuven, Division of Gynaecological Oncology, Gasthuisberg, Herestraat 49, Leuven, BE-3000, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
